Hybrid compounds based on a combination of the first-line antitubercular pyrazinamide (PZA) and a formerly identified antimycobacterial scaffold of 4-arylthiazol-2-amine were designed. Eighteen compounds were prepared, characterized and tested for in vitro growth inhibition activity against M. tuberculosis H37Rv, M. kansasii, M. avium and M. smegmatis by Microplate Alamar Blue Assay at neutral pH. Active compounds were tested for in vitro cytotoxicity in the human hepatocellular carcinoma cell line (HepG2). The most active 6-chloro-N-[4-(4-fluorophenyl)thiazol-2-yl]pyrazine-2-carboxamide (9b) also had the broadest spectrum of activity and inhibited M. tuberculosis, M. kansasii, and M. avium with MIC = 0.78 μg mL-1 (2.3 μM) and a selectivity index related to HepG2 cells of SI > 20. Structure-activity relationships within the series are discussed. Based on its structural similarity to known inhibitors and the results of a molecular docking study, we suggest mycobacterial beta-ketoacyl-(acyl-carrier-protein) synthase III (FabH) as a potential target.

Department of Clinical Microbiology University Hospital Sokolská 581 Hradec Králové 500 05 Czech Republic

Faculty of Pharmacy in Hradec Králové Charles University Heyrovského 1203 Hradec Králové 500 05 Czech Republic Email

Zobrazit více v PubMed

World Health Organization, Global Tuberculosis Report 2017, WHO/HTM/TB/2017.23, Accessed Jan 10, 2017, Available from: http://www.who.int/tb/publications/global_report/en/.

Houben R. M. G. J., Dodd P. J. PLoS Med. 2016;13:e1002152. PubMed PMC

World Health Organization, Global Plan to Stop Tuberculosis, WHO/HTM/STB/2006.35, Accessed Jun 26, 2017. Available from: http://www.who.int/tb/publications/global_plan_to_stop_tb/en/.

World Health Organization, Global Tuberculosis Report 2016, WHO/HTM/TB/2016.13, Accessed Feb 2, 2017. Available from: http://www.who.int/tb/publications/global_report/en/.

World Health Organization, WHO treatment guidelines for drug-resistant tuberculosis (2016 update), WHO/HTM/TB/2016.04, Accessed Aug 15, 2017. Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/. PubMed

Cheng K., Xue J.-Y., Zhu H.-L. Bioorg. Med. Chem. Lett. 2013;23:4235–4238. PubMed

Li J. R., Li D. D., Wang R. R., Sun J., Dong J. J., Du Q. R., Fang F., Zhang W. M., Zhu H. L. Eur. J. Med. Chem. 2014;75:438–447. PubMed

Bhatt A., Molle V., Besra G. S., Jacobs W. R., Kremer L. Mol. Microbiol. 2007;64:1442–1454. PubMed

Ananthan S., Faaleolea E. R., Goldman R. C., Hobrath J. V., Kwong C. D., Laughon B. E., Maddry J. A., Mehta A., Rasmussen L., Reynolds R. C., Secrist J. A., Shindo N., Showe D. N., Sosa M. I., Suling W. J., White E. L. Tuberculosis. 2009;89:334–353. PubMed PMC

Mjambili F., Njoroge M., Naran K., De Kock C., Smith P. J., Mizrahi V., Warner D., Chibale K. Bioorg. Med. Chem. Lett. 2014;24:560–564. PubMed

Meissner A., Boshoff H. I., Vasan M., Duckworth B. P., Barry C. E., Aldrich C. C. Bioorg. Med. Chem. 2013;21:6385–6397. PubMed PMC

Kesicki E. A., Bailey M. A., Ovechkina Y., Early J. V., Alling T., Bowman J., Zuniga E. S., Dalai S., Kumar N., Masquelin T., Hipskind P. A., Odingo J. O., Parish T. PLoS One. 2016;11:e0155209. PubMed PMC

Pieroni M., Wan B. J., Cho S. H., Franzblau S. G., Costantino G. Eur. J. Med. Chem. 2014;72:26–34. PubMed

Roy K. K., Singh S., Sharma S. K., Srivastava R., Chaturvedi V., Saxena A. K. Bioorg. Med. Chem. Lett. 2011;21:5589–5593. PubMed

Zhang Y., Mitchison D. Int. J. Tuberc. Lung. Dis. 2003;7:6–21. PubMed

Zimhony O., Cox J. S., Welch J. T., Vilcheze C., Jacobs W. R. Nat. Med. 2000;6:1043–1047. PubMed

Boshoff H. I., Mizrahi V., Barry C. E. J. Bacteriol. 2002;184:2167–2172. PubMed PMC

Ngo S. C., Zimhony O., Chung W. J., Sayahi H., Jacobs W. R., Welch J. T. Antimicrob. Agents Chemother. 2007;51:2430–2435. PubMed PMC

Zimhony O., Vilcheze C., Arai M., Welch J. T., Jacobs W. R. Antimicrob. Agents Chemother. 2007;51:752–754. PubMed PMC

Sayahi H., Zimhony O., Jacobs W. R., Shekhtman A., Welch J. T. Bioorg. Med. Chem. Lett. 2011;21:4804–4807. PubMed PMC

Zhang S., Chen J., Shi W., Liu W., Zhang W., Zhang Y. Emerging Microbes Infect. 2013;2:e34. PubMed PMC

Shi W. L., Chen J. Z., Feng J., Cui P., Zhang S., Weng X. H., Zhang W. H., Zhang Y. Emerging Microbes Infect. 2014;3:e58. PubMed PMC

Pandey B., Grover S., Tyagi C., Goyal S., Jamal S., Singh A., Kaur J., Grover A. Gene. 2016;581:31–42. PubMed

Kim H., Shibayama K., Rimbara E., Mori S. PLoS One. 2014;9:e100062. PubMed PMC

Shi W. L., Zhang X. L., Jiang X., Yuan H. M., Lee J. S., Barry C. E., Wang H. H., Zhang W. H., Zhang Y. Science. 2011;333:1630–1632. PubMed PMC

Yang J. J., Liu Y. D., Bi J., Cai Q. X., Liao X. L., Li W. Q., Guo C. Y., Zhang Q., Lin T. W., Zhao Y. F., Wang H. H., Liu J., Zhang X. L., Lin D. H. Mol. Microbiol. 2015;95:791–803. PubMed

Stehr M., Elamin A. A., Singh M. Expert Rev. Anti-Infect. Ther. 2015;13:593–603. PubMed

Dolezal M., Palek L., Vinsova J., Buchta V., Jampilek J., Kralova K. Molecules. 2006;11:242–256. PubMed PMC

Dolezal M., Kesetovic D., Zitko J. Curr. Pharm. Des. 2011;17:3506–3514. PubMed

Zitko J., Servusova B., Paterova P., Mandikova J., Kubicek V., Kucera R., Hrabcova V., Kunes J., Soukup O., Dolezal M. Molecules. 2013;18:14807–14825. PubMed PMC

Zitko J., Servusova-Vanaskova B., Paterova P., Navratilova L., Trejtnar F., Kunes J., Dolezal M. Chem. Pap. 2016;70:649–657.

Servusova B., Vobickova J., Paterova P., Kubicek V., Kunes J., Dolezal M., Zitko J. Bioorg. Med. Chem. Lett. 2013;23:3589–3591. PubMed

Servusova B., Eibinova D., Dolezal M., Kubicek V., Paterova P., Pesko M., Kralova K. Molecules. 2012;17:13183–13198. PubMed PMC

Koppireddi S., Komsani J. R., Avula S., Pombala S., Vasamsetti S., Kotamraju S., Yadla R. Eur. J. Med. Chem. 2013;66:305–313. PubMed

Merget B., Zilian D., Muller T., Sotriffer C. A. Bioinformatics. 2013;29:62–68. PubMed

Lu X. Y., Tang J., Zhang Z., Ding K. Curr. Med. Chem. 2015;22:651–667. PubMed

Devine S. M., Mulcair M. D., Debono C. O., Leung E. W. W., Nissink J. W. M., Lim S. S., Chandrashekaran I. R., Vazirani M., Mohanty B., Simpson J. S., Baell J. B., Scammells P. J., Norton R. S., Scanlon M. J. J. Med. Chem. 2015;58:1205–1214. PubMed

Baell J. B., Nissink J. W. M. ACS Chem. Biol. 2017;13:36–44. PubMed PMC

Azzali E., Machado D., Kaushik A., Vacondio F., Flisi S., Cabassi C. S., Lamichhane G., Viveiros M., Costantino G., Pieroni M. J. Med. Chem. 2017;60:7108–7122. PubMed

Zinc, Accessed Jan 12, 2018, Available from: http://zinc15.docking.org/substances/subsets/fda/.

Servusova B., Paterova P., Mandikova J., Kubicek V., Kucera R., Kunes J., Dolezal M., Zitko J. Bioorg. Med. Chem. Lett. 2014;24:450–453. PubMed

Prashanth T., Thirusangu P., Vijay Avin B. R., Lakshmi Ranganatha V., Prabhakar B. T., Khanum S. A. Eur. J. Med. Chem. 2014;87:274–283. PubMed

Muthyala M. K., Kumar A. J. Heterocycl. Chem. 2012;49:959–964.

Muchowski P. J., Muchowski J. M., Schwarcz R. and Guidetti P., Preparation of substituted N-thiazolyl benzenesulfonamides as inhibitors of kynurenine-3-monooxygenase, WO2008022281A1, 2008.

Franzblau S. G., Witzig R. S., McLaughlin J. C., Torres P., Madico G., Hernandez A., Degnan M. T., Cook M. B., Quenzer V. K., Ferguson R. M., Gilman R. H. J. Clin. Microbiol. 1998;36:362–366. PubMed PMC

Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole

N-Pyrazinoyl Substituted Amino Acids as Potential Antimycobacterial Agents-The Synthesis and Biological Evaluation of Enantiomers